Measurement of residual BCL1 tumor cells in the spleen by immunofluorescent staining.

Spleen cells from BCL-1 recipients after transplantation were stained with fluorescein isothiocyanate (FITC)-conjugated anti-BCL1-ID monoclonal antibody and FITC-conjugated rat IgG Za isotype control. (A) Recipients of bone marrow cells alone plus BCL1 50 days after bone marrow transplantation (BMT). (B) Recipients of bone marrow plus spleen cells and BCL1 cells 50 days after BMT. (C) Recipients of bone marrow plus spleen cells and BCL1 cells treated with PG27 100 days after BMT. Note that the far peak is markedly decreased, suggesting that there is no BCL1 detectable. One of 4 replicated experiments was shown.